Biocross presents a fast and cost-effective method for apolipoprotein E isotyping for patient stratification in clinical trials
Biocross presents a fast and cost-effective method for apolipoprotein E isotyping as an alternative to APOE genotyping for patient stratification in clinical trials at the 2015 Clinical Trials for Alzheimer’s disease (CTAD) meeting in November 2015. Isoform E4 of...
CTAD 2014 presentation of a blood-based 7-metabolite signature for the early diagnosis of Alzheimer´s disease.
Biocross S.L., an innovative developer of assays for risk assessment and prediction of AD, has announced that it will be presenting a poster at the Clinical Trials on Alzheimer’s disease Conference, CTAD 2014, Philadelphia, United States, November 20-22nd, discussing...
Biocross is involved in a new clinical study
Biocross is involved in a new multicenter study in which 17 hospitals from Spain, France, and Belgium are participating. The objective is to recruit over 500 patients, classified as healthy individuals or patients with AD, mild cognitive impairment, or other...
Approval of a clinical study for the identification in blood of markers.
Biocross announces approval of a clinical study for the identification in blood of markers for the diagnosis of Alzheimer’s disease using a multiparametric test – September 2011 The project, entitled “Identification of markers in blood for multiparametric...
